NCT01188811

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

Lipoic Acid for Neuroprotection in Secondary Progressive MS

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: VA Office of Research and Development · Federal
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.

Detailed description

There are no approved medications that are neuroprotective or able to slow disability accumulation in secondary progressive multiple sclerosis (SPMS). This two-year study will determine if daily oral intake of lipoic acid, a natural supplement, will prove superior to placebo in reducing injury to the brain and reducing disability progression in SPMS. Neuroprotection will be measured by the extent of brain volume loss seen on MRI, and disability will be measured by neurological status and quality of life.

Conditions

• Multiple Sclerosis, Chronic Progressive

Interventions

Type	Name	Description
DRUG	lipoic acid	1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
DRUG	Placebo	The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation

Timeline

• Start date: 2010-10-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2010-08-26
• Last updated: 2017-02-02
• Results posted: 2017-02-02

Locations

1 site across 1 country: United States